Benchling completed the acquisitions of ReSync Bio and Sphinx Bio.

Benchling, a biotechnology software company specializing in R&D cloud platforms, completed the acquisitions of ReSync Bio, an AI-powered R&D software provider, and Sphinx Bio, a developer of real-time experimental data analysis tools. Financial terms were not disclosed. “The biopharma industry spends more than $250bn per year on R&D, only for most medicines to fail in clinical trials. The potential for AI to transform drug discovery is enormous, but largely untapped. The teams at ReSync and Sphinx share our mission to change that. Together we will build tools that can help scientists deliver more therapies to patients, faster,” Sajith Wickramasekara, Benchling CEO and Co-founder.